Latest News and Press Releases

– Company to pursue Phase 3 development strategy designed to deliver best-in-class efficacy with a high-dose quarterly regimen in broad patient populations in both severe asthma and CRSwNP – –...

Allows USAR to Begin Fulfilling Customer Orders in 2Q26, With Further Capacity Expansion to Follow Critical Step in USAR’s Effort to Secure, Reshore and Grow a Globally Integrated Rare Earth Value...

BETHESDA, Md., March 26, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of...

Abaxx Futures Now Available Through TMX Trayport’s Joule Platform

TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Labrador Gold Corp. (TSX.V: LAB | FNR: 2N6) (“LabGold” or the “Company”) welcomes the recent announcement by the Ontario government that it now plans to...

Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026Lead clinical candidate IND filing in...

Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected to reach target enrollment (n=300) in April 2026, with topline results expected in the third quarter of 2026Phase 2 IRIS trial for ML-004...

Intranasal oxytocin blocks the release of calcitonin gene-related peptide (CGRP) in animal models and is the core technology of TNX-1900 for craniofacial pain conditions, including migraine and...

Agomab today announced that the USPTO granted a patent covering the composition of matter of AGMB-447.

VANCOUVER, British Columbia, March 26, 2026 (GLOBE NEWSWIRE) -- VR Resources Limited (“VR” or the “Company”, TSX.V: VRR, FSE: 5VR0; OTCQB: VRRCF) is pleased to announce that it has completed the...